Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

BJP on Tuesday slammed the ruling Congress party in Karnataka for holding its 'Sadhana Samavesha' event to mark two years in ...

TARRYTOWN, N.Y. and WASHINGTON, May 16, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Adam Kovalčík, 19 ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Imperial College London is establishing a research and innovation hub in Bengaluru, its fourth international location. This ...

Yancopoulos Innovator Award at the 75 th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named ...

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals REGN, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...